Bragar Eagel & Squire, P.C. Is Investigating Agrify, Carvana, Enochian, and Corcept and Encourages Investors to Contact the Firm

NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ: AGFY), Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), and Corcept Therapeutics, Inc. (NASDAQ: CORT). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.


Agrify Corporation (NASDAQ: AGFY)

On December 16, 2021, during trading hours, market analyst Bonitas Research published a report regarding Agrify which alleges several issues at the Company including that “[w]e believe that Agrify created artificial demand for its product by financing undisclosed Company insiders to act as independent customers.” Further the report alleges that “Agrify insiders lied to investors about the independence of its customer base in order to execute a dubious stock promotion for self-enrichment at the expense of minority shareholders[,]” and that “[e]vidence showed that five (5) of Agrify’s eight (8) customer announcements in 2021 are either with undisclosed Company insiders or with unlicensed unproven operators.”

On this news, Agrify’s common stock price fell sharply during intraday trading on December 16, 2021.

For more information on the Agrify investigation go to:

https://bespc.com/cases/AGFY


Carvana Co. (NYSE: CVNA)

On May 18, 2022, the Illinois Secretary of State’s office announced that Carvana’s license to sell vehicles in Illinois was suspended on May 10 due to the misuse of issuing out-of-state temporary registration permits and for failing to transfer titles. The Secretary of State’s office stated that vehicles that have already been purchased but not yet delivered can still be delivered to the purchasers during the suspension, but no new vehicle sales can occur in Illinois during the suspension order.

On this news, Carvana’s stock price fell $6.55 per share, or 15.75%, to close at $35.05 per share on May 18, 2022.

For more information on the Carvana investigation go to:

https://bespc.com/cases/CVNA


Enochian Biosciences, Inc. (NASDAQ: ENOB)

On May 25, 2022, the United State Attorney’s Office for the District of Vermont, announced that the co-founder of Enochian was arrested Wednesday following a two-year investigation into a man who was kidnapped and found dead in January 2018. Dr. Serhat Gumrukcu is being charged with conspiring to use interstate commerce facilities in the commission of murder-for-hire, which resulted in the death of Gregory Davis, a resident of Vermont.

On this news, Enochian’s stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.

Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.

For more information on the Enochian investigation go to:

https://bespc.com/cases/ENOB


Corcept Therapeutics, Inc. (NASDAQ: CORT)

On December 8, 2021, Corcept disclosed in a filing with the U.S. Securities and Exchange Commission that “[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney’s Office for the District of New Jersey (the ‘NJ USAO’) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, Corcept’s relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym.” Corcept further disclosed that “[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena.”

On this news, Corcept’s stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

For more information on the Corcept investigation go to:

https://bespc.com/cases/CORT


About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit


www.bespc.com


. Attorney advertising. Prior results do not guarantee similar outcomes.


Contact Information:

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

(212) 355-4648


[email protected]



www.bespc.com


Primary Logo